Evidence map›Paper›PMID 38782996›Full record

ArticleScientific reports2024

Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.

Jiu-Ling Chen, Chuang-Yan Wu, Xiang-Yu Luo, Xue-Ying Wang, Fang-Ming Wang, Xin Huang, Wei Yuan, Qiang Guo

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiu-Ling Chen *Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chuang-Yan Wu *Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiang-Yu LuoDepartment of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Xue-Ying WangDepartment of Basic Medicine, Hubei University of Medicine, Shiyan, China.
Fang-Ming WangDepartment of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xin HuangDepartment of Thoracic Surgery, People's Hospital of Dongxihu District, Wuhan, China. 13986091435@163.com.
Wei YuanDepartment of Basic Medicine, Hubei University of Medicine, Shiyan, China. yw2017dna@163.com.
Qiang GuoDepartment of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China. guoqianglidan@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Killer cell lectin-like receptor B1 (KLRB1) is implicated in cancer progression and immunity. In this study, we aimed to evaluate the expression levels of KLRB1 in lung adenocarcinoma (LUAD) and analyze the relationship between KLRB1 expression levels, LUAD progression, and the tumor immune microenvironment. KLRB1 levels in LUAD were analyzed using data from the TCGA and XENA databases. Additionally, the diagnostic values of KLRB1 were analyzed in patients with LUAD. Survival and meta-analyses were employed to investigate the relationship between KLRB1 levels and other prognostic factors in patients with LUAD. Bioinformatics and cellular experiments were used to understand the functions and mechanisms of KLRB1. In addition, correlation analysis was used to investigate the relationship between KLRB1 levels and the immune microenvironment in LUAD. Reduced KLRB1 expression in LUAD was found to positively correlate with tumor size, distant metastasis, pathological stage, age, overall survival, diagnostic value, and disease-specific survival in patients with LUAD (P < 0.05). Conversely, increased KLRB1 expression was found to positively correlate with the overall survival and disease-specific survival in patients with LUAD (P < 0.05). We also found that the overexpression of KLRB1 can inhibit the proliferation, migration, and invasion of LUAD cells and promote apoptosis. KLRB1 was involved in immune cell differentiation, NF-kB, PD-L1, and PD-1 checkpoint pathways and others. Additionally, KLRB1 expression was linked to tumor purity, stromal, immune, and estimate scores, the levels of immune cells including B cells, CD8

Indexed as

Adenocarcinoma of LungCell ProliferationLung NeoplasmsTumor MicroenvironmentBiomarkers, TumorCell Line, TumorDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisNK Cell Lectin-Like Receptor Subfamily BPrognosisBiomarkers, TumorKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily BDisease-specific survivalKLRB1Lung adenocarcinomaPrognosisROC

Identifiers

PMID38782996
PMCPMC11116539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.